Surveillance of Respiratory Pathogens and Brand-Specific Vaccine Effectiveness in Adults Hospitalised with SARI: An Observational Study (former id.DRIVE surveillance study of respiratory pathogens in adults hospitalised for severe acute respiratory infection (SARI) across Europe)

28/02/2024
28/09/2026
EU PAS number:
EUPAS1000000012
Study
Ongoing
Subscribe
Download as PDF
Study summary
No information provided.
Study identification

EU PAS number

EUPAS1000000012

Study ID

1000000012

Official title and acronym

Surveillance of Respiratory Pathogens and Brand-Specific Vaccine Effectiveness in Adults Hospitalised with SARI: An Observational Study (former id.DRIVE surveillance study of respiratory pathogens in adults hospitalised for severe acute respiratory infection (SARI) across Europe)

DARWIN EU® study

No

Study countries

Austria
Belgium
Canada
France
Germany
Italy
Spain
United Kingdom

Study description

id.DRIVE’s Study Network will be leveraged to continuously monitor severe acute respiratory infection (SARI)-causing pathogens (e.g., severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza, and respiratory syncytial virus [RSV]), including virological and clinical trends, as well as burden of disease (e.g., pathogen-specific morbidity; in-hospital mortality).
The surveillance of additional pathogens allows for study preparedness, with the potential to perform feasibility assessments for future impact and effectiveness studies within the id.DRIVE Study Network.

Update 01 Sep 2026:
From 01 Sep 2026 (start of the id.DRIVE epidemiological year 2026-2027), the three id.DRIVE master study protocols (EUPAS1000000012, EUPAS42328, and EUPAS1000000035) are merged into one common master protocol (EUPAS1000000012). This means that the respiratory pathogen surveillance protocol (EUPAS1000000012; ongoing) now also incorporates the RSV vaccine effectiveness (EUPAS1000000035; ongoing; RSV VE module) and COVID-19 vaccine effectiveness (EUPAS42328; paused; CVE module) studies. EUPAS42328 and EUPAS1000000035 are updated accordingly in this register (the reader of those two is now referred to EUPAS1000000012).

Study status

Ongoing
Research institutions and networks

Institutions

Imperial College London
United Kingdom
First published:
01/02/2024
Institution Educational Institution
Grand Hôpital de Charleroi
UZA University Hospital Antwerp
CHU Saint-Pierre Hospital Brussels

Klinik Favoriten Hospital

Valencia Hospital Network for the Study of Influenza and Other Respiratory Viruses (VAHNSI)
Germans Trias i Pujol University Hospital
Hospital Clínico Universitario de Santiago de Compostela
Hospital Universitario La Paz
Hospital Clínic Universitari Barcelona

Centro Interuniversitario per la Ricerca sull’Influenza e le altre Infezioni (CIRI-IT)
Ospedale Luigi Sacco

Universitätsklinikum Freiburg
Universitätsklinikum Frankfurt
Universitätsklinikum Ulm
Charité - Universitätsmedizin Berlin
Universitätsklinikum Düsseldorf
Universitätsklinikum Essen

Hôpitaux Universitaires Henri-Mondor
Centre Hospitalier Annecy Genevois and St Julien/Sallanches

Manchester University NHS Foundation Trust (MFT)
NHS Lothian

The Ottawa Hospital
Calgary Corridor Hospitals
The Toronto Invasive Bacterial Diseases Network (TIBDN)

Networks

id.DRIVE (former COVIDRIVE)
Austria
Belgium
Canada
Croatia
Czechia
Denmark
France
Germany
Iceland
Italy
Poland
Romania
Spain
United Kingdom
First published:
04/05/2026
Network
ENCePP partner

Contact details

Kaatje Bollaerts

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Current and former partners of COVIDRIVE and id.DRIVE:
AstraZeneca, Bavarian Nordic, CureVac, GSK, Johnson & Johnson, Moderna, Novavax, Pfizer, Sanofi, and Valneva
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable